Peroxynitrite decomposition catalyst reduces vasopressin requirement in ovine MRSA sepsis.
Arginine vasopressin
Peroxynitrite decomposition catalyst
Refractory shock
Septic shock
Vascular hypo-responsiveness
WW-85
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
09 Sep 2019
09 Sep 2019
Historique:
received:
05
11
2018
accepted:
18
02
2019
entrez:
13
9
2019
pubmed:
13
9
2019
medline:
13
9
2019
Statut:
epublish
Résumé
Sepsis is one of the most frequent causes of death in the intensive care unit. Host vascular hypo-responsiveness to vasopressors during septic shock is one of the challenging problems. This study tested the hypothesis that adjunct therapy with peroxynitrite decomposition catalyst (WW-85) would reduce arginine vasopressin (AVP) requirements during sepsis resuscitation, using ovine sepsis model. Thirteen adult female Merino sheep, previously instrumented with multiple vascular catheters, were subjected to "two-hit" (cotton smoke inhalation and intrapulmonary instillation of live methicillin-resistant Staphylococcus aureus; 3.5 × 10 The injury induced severe hypotension refractory to aggressive fluid resuscitation. High doses of AVP were required to partially attenuate the sepsis-induced hypotension. However, the cumulative AVP requirement was significantly reduced by adjunct treatment with WW-85 at 17-24 h after the injury (p < 0.05). Total AVP dose and the highest AVP rate were significantly lower in the WW-85 + AVP group compared to the AVP group (p = 0.02 and 0.04, respectively). Treatment with WW-85 had no adverse effects. In addition, the in vitro effects of AVP on isolated artery diameter changes were abolished with peroxynitrite co-incubation. The modulation of reactive nitrogen species, such as peroxynitrite, may be considered as a novel adjunct treatment option for septic shock associated with vascular hypo-responsiveness to vasopressors.
Sections du résumé
BACKGROUND
BACKGROUND
Sepsis is one of the most frequent causes of death in the intensive care unit. Host vascular hypo-responsiveness to vasopressors during septic shock is one of the challenging problems. This study tested the hypothesis that adjunct therapy with peroxynitrite decomposition catalyst (WW-85) would reduce arginine vasopressin (AVP) requirements during sepsis resuscitation, using ovine sepsis model.
METHODS
METHODS
Thirteen adult female Merino sheep, previously instrumented with multiple vascular catheters, were subjected to "two-hit" (cotton smoke inhalation and intrapulmonary instillation of live methicillin-resistant Staphylococcus aureus; 3.5 × 10
RESULTS
RESULTS
The injury induced severe hypotension refractory to aggressive fluid resuscitation. High doses of AVP were required to partially attenuate the sepsis-induced hypotension. However, the cumulative AVP requirement was significantly reduced by adjunct treatment with WW-85 at 17-24 h after the injury (p < 0.05). Total AVP dose and the highest AVP rate were significantly lower in the WW-85 + AVP group compared to the AVP group (p = 0.02 and 0.04, respectively). Treatment with WW-85 had no adverse effects. In addition, the in vitro effects of AVP on isolated artery diameter changes were abolished with peroxynitrite co-incubation.
CONCLUSIONS
CONCLUSIONS
The modulation of reactive nitrogen species, such as peroxynitrite, may be considered as a novel adjunct treatment option for septic shock associated with vascular hypo-responsiveness to vasopressors.
Identifiants
pubmed: 31512009
doi: 10.1186/s40635-019-0227-4
pii: 10.1186/s40635-019-0227-4
pmc: PMC6738358
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM097480
Pays : United States
Organisme : NIGMS NIH HHS
ID : GM097480
Pays : United States
Organisme : Shriners Hospitals for Children
ID : SHC84050, SHC85100
Références
Science. 1999 Nov 19;286(5444):1583-7
pubmed: 10567269
Crit Care Clin. 2000 Apr;16(2):179-92
pubmed: 10768078
J Cereb Blood Flow Metab. 2001 Mar;21(3):253-61
pubmed: 11295880
Crit Care Med. 2001 Jul;29(7):1303-10
pubmed: 11445675
Intensive Care Med. 2002 Feb;28(2):108-21
pubmed: 11907653
Anesthesiology. 2002 Sep;97(3):671-81
pubmed: 12218535
Intensive Care Med. 2003 Mar;29(3):352-60
pubmed: 12536268
N Engl J Med. 2003 Apr 17;348(16):1546-54
pubmed: 12700374
Crit Care Med. 2003 May;31(5):1394-8
pubmed: 12771608
Crit Care Med. 2004 Jan;32(1):13-20
pubmed: 14707555
Crit Care Med. 2004 Jan;32(1):21-30
pubmed: 14707556
Lancet. 2005 Jan 1-7;365(9453):63-78
pubmed: 15639681
Crit Care Med. 2006 Apr;34(4):1126-30
pubmed: 16484914
Shock. 2006 May;25(5):522-7
pubmed: 16680018
J Appl Physiol (1985). 2007 Apr;102(4):1402-9
pubmed: 17204577
Shock. 2008 May;29(5):642-9
pubmed: 17885644
J Pharmacol Exp Ther. 2008 May;325(2):475-83
pubmed: 18272810
Front Biosci (Landmark Ed). 2009 Jan 01;14:1979-89
pubmed: 19273179
Shock. 2009 Dec;32(6):621-5
pubmed: 19295474
Shock. 2010 Sep;34 Suppl 1:4-14
pubmed: 20523270
Crit Care. 2010;14(4):R129
pubmed: 20602787
Heart Lung. 2011 May-Jun;40(3):247-52
pubmed: 20630594
Biochem Biophys Res Commun. 2010 Aug 20;399(2):286-91
pubmed: 20655878
Intensive Care Med. 2010 Dec;36(12):2019-29
pubmed: 20862451
Semin Thorac Cardiovasc Surg. 2010 Summer;22(2):140-4
pubmed: 21092891
Intensive Care Med. 2011 Sep;37(9):1432-7
pubmed: 21779849
Crit Care Med. 2012 Mar;40(3):754-61
pubmed: 21963582
Intensive Care Med. 2012 Jan;38(1):9-19
pubmed: 22127480
Chest. 2013 Mar;143(3):664-671
pubmed: 22911566
Curr Vasc Pharmacol. 2013 Mar 1;11(2):196-207
pubmed: 23506498
Crit Care Med. 2014 Jul;42(7):e525-e533
pubmed: 24674922
Anesthesiology. 2014 Nov;121(5):930-6
pubmed: 25198173
Expert Opin Ther Pat. 2015 Apr;25(4):443-66
pubmed: 25576197
Shock. 2015 Oct;44(4):305-9
pubmed: 26125087
PLoS One. 2015 Dec 07;10(12):e0144345
pubmed: 26640957
Chest. 1989 Oct;96(4):885-92
pubmed: 2676394
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Chest. 2018 Aug;154(2):416-426
pubmed: 29329694
J Int Med Res. 2018 Apr;46(4):1303-1310
pubmed: 29332515
Crit Care. 2018 Feb 27;22(1):52
pubmed: 29486781
Shock. 2018 Oct;50(4):377-380
pubmed: 30106875
JAMA. 1996 Apr 17;275(15):1192-6
pubmed: 8609688
Br J Pharmacol. 1997 Jan;120(2):259-67
pubmed: 9117118
Clin Infect Dis. 1998 Jul;27(1):185-90
pubmed: 9675475